MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.…
MAIA Biotechnology Reports Consistent Strong Efficacy in Expanded Phase 2 THIO-101 Study in Non-Small Cell Lung Cancer
MAIA Biotechnology (NYSEAMERICAN: MAIA) is listed on NYSE American, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 13 employees.
The shares were at 1.110 USD on 20 November 2026, up 0.9% over 52 weeks. Its 52-week range is 0.8700 USD to 3.190 USD: the price is 65.2% below the high and 27.6% above the low.
Its market capitalisation is 68.54M USD.
MAIA Biotechnology reports an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 21.34M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.